However, while high CAF risk group harbored relative richer infiltrations of Th1 cells, cytotoxic cells and CD8 T cells, TIDE algorithm manifested that high CAF risk CRC patients were more likely not to respond to anti-PD-1 and anti-CTLA-4 therapies in all three datasets. The gene discussed is CTLA4; the disease is colorectal carcinoma.